Equinox Gold Corp. Common Shares vs uniQure N.V. Ordinary Shares — how do they compare? Equinox Gold Corp. Common Shares trades at $10.57 (market cap $12.62B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Equinox Gold Corp. Common Shares is far larger — about 8.5× uniQure N.V. Ordinary Shares's market cap, and Equinox Gold Corp. Common Shares pays a 0.48% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinox Gold Corp. Common Shares for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| EQX | QURE | |
|---|---|---|
Market Cap | $12.62B | $1.48B |
Volume | 12,370,191 | 2,488,780 |
Sector | Basic Materials | Health |
52-Week High | $18.76 | $70.59 |
52-Week Low | $8.62 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $12.72B | $728.62M |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
Equinox Gold (EQX) trades at $10.85, down 3.12% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results with $1.82B revenue and $221M net income, and projects significant growth in 2026 to $2.9B revenue. Recent news highlights the completion of the Orla Mining merger, positioning EQX as a major North American gold producer with a path to 2 million ounces of annual production.
The outlook is positive due to transformative growth from the Orla acquisition, increased production guidance, and a 50% dividend hike. Risks include execution of mine expansions and gold price volatility. With a 100% buy rating from one analyst, the stock appears undervalued relative to its growth pipeline, though recent earnings misses warrant monitoring.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Equinox Gold is a gold mining company with operations in the Americas. It produces gold and develops additional mining projects.
Read more on EQX →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →